What supportive therapies can help maintain mobility and quality of life as the disease progresses?

Physical therapy focusing on gentle range‑of‑motion exercises can delay contracture development. Occupational therapy can adapt daily activities and recommend assistive devices like walkers or wheelchairs. Speech therapy can address swallowing difficulties and communication needs. Regular psychosocial support for the family, including counseling and respite care, is also crucial to maintain overall well‑being.===

When should a child with CLN2 disease start enzyme replacement therapy, and how is it given?

Enzyme replacement therapy (cerliponase alfa) is usually initiated once a definitive diagnosis is confirmed, often between ages 2 and 4. It is administered as a monthly infusion into the cerebrospinal fluid via an implanted Ommaya reservoir. The first infusion is typically done in a hospital setting, after which the child can receive the treatment at home or in a clinic. Regular monitoring of neurological status and infusion site is essential.

What early signs of vision loss should parents watch for, and how can they be monitored?

Parents should look for delayed visual tracking, decreased eye contact, or a tendency to look away from bright lights. A pediatric ophthalmologist can perform a bedside visual acuity test and fundoscopic exam every 3–6 months. Early detection allows for low‑vision aids and adaptive strategies to maintain independence.

Which antiepileptic medications are most effective for controlling seizures in CLN2 disease?

Levetiracetam and valproic acid are commonly used first‑line agents because they have a favorable side‑effect profile in children. If seizures are refractory, a combination of levetiracetam with topiramate or clobazam may be considered. Seizure control should be individualized, and drug levels should be checked regularly to avoid toxicity.

CLN2 disease

CLN2 disease is an inherited lysosomal storage disorder that begins in early childhood with seizures, ataxia, and vision loss, leading to progressive neurodegeneration and a shortened lifespan.

Overview

CLN2 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms typically begin between ages 2 and 4. The initial features usually include recurrent seizures (epilepsy) and difficulty coordinating movements (ataxia). Affected children also develop muscle twitches (myoclonus) and vision loss. The disease impacts motor skills such as sitting and walking, and speech development. It also causes loss of previously acquired skills (developmental regression), gradually worsening intellectual disability, and behavioral problems. Most individuals require a wheelchair by late childhood and typically do not survive past their teens.

Some children do not develop symptoms until after age 4. These individuals tend to have milder overall features but more severe ataxia. They have a shortened life expectancy, although many survive into adulthood.

CLN2 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), collectively referred to as Batten disease. All these disorders affect the nervous system and usually cause progressive vision loss, movement problems, and cognitive decline. The different NCLs are distinguished by their genetic cause and are designated “CLN” followed by a number indicating the subtype.

Frequency

In the Newfoundland province of Canada, the incidence of CLN2 disease is estimated at 9 in 100,000 births. The incidence outside this population is unknown. More than 300 cases worldwide have been described in the scientific literature.

Causes

Mutations in the TPP1 gene cause CLN2 disease. The TPP1 gene provides instructions for producing an enzyme called tripeptidyl peptidase 1. This enzyme is found in cell structures called lysosomes, which digest and recycle various molecules. Tripeptidyl peptidase 1 breaks down protein fragments (peptides) into their individual building blocks.

Mutations in the TPP1 gene greatly reduce or eliminate production or activity of the enzyme. A reduction in functional enzyme results in incomplete breakdown of certain peptides. Like other NCLs, CLN2 disease is characterized by accumulation of proteins, peptides, and other substances in lysosomes. These accumulations occur throughout the body, but nerve cells are particularly vulnerable. The buildup causes cell damage and death, leading to the clinical signs of the disease.

Individuals diagnosed later in childhood likely have TPP1 mutations that allow production of an enzyme with some residual function. Higher residual activity delays peptide accumulation and nerve‑cell damage, resulting in a later onset.

Learn more about the gene associated with CLN2 disease

TPP1

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene but typically do not show signs or symptoms.

Other Names for This Condition

Jansky‑Bielschowsky disease
Late‑infantile Batten disease
Late‑infantile neuronal ceroid lipofuscinosis
LINCL
Neuronal ceroid lipofuscinosis, late‑infantile

Additional Information & Resources

Genetic Testing Information

Genetic Testing Registry: Neuronal ceroid lipofuscinosis 2
Genetic Testing Registry: Late‑infantile neuronal ceroid lipofuscinosis
Genetic Testing Registry: Neuronal ceroid lipofuscinosis

Genetic and Rare Diseases Information Center

CLN2 disease

Patient Support and Advocacy Resources

National Organization for Rare Disorders (NORD)

Clinical Trials

ClinicalTrials.gov

Catalog of Genes and Diseases from OMIM

CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2

Scientific Articles on PubMed

PubMed

References

Elleder M, Dvorakova L, Stolnaja L, Vlaskova H, Hulkova H, Druga R, Poupetova H, Kostalova E, Mikulastik J. Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency. Acta Neuropathol. 2008 Jul;116(1):119-24. doi:10.1007/s00401-008-0349-3. Epub 2008 Feb 19.
Fietz M, AlSayed M, Burke D, Cohen‑Pfeffer J, Cooper JD, Dvorakova L, Giugliani R, Izzo E, Jahnova H, Lukacs Z, Mole SE, Noher de Halac I, Pearce DA, Poupetova H, Schulz A, Specchio N, Xin W, Miller N. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab. 2016 Sep;119(1‑2):160-7. doi:10.1016/j.ymgme.2016.07.011. Epub 2016 Jul 25.
Getty AL, Pearce DA. Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function. Cell Mol Life Sci. 2011 Feb;68(3):453-74. doi:10.1007/s00018-010-0468-6. Epub 2010 Aug 1.
Kohan R, Carabelos MN, Xin W, Sims K, Guelbert N, Cismondi IA, Pons P, Alonso GI, Troncoso M, Witting S, Pearce DA, Dodelson de Kremer R, Oller‑Ramirez AM, Noher de Halac I. Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America. Gene. 2013 Mar 1;516(1):114-21. doi:10.1016/j.gene.2012.12.058. Epub 2012 Dec 22.
Moore SJ, Buckley DJ, MacMillan A, Marshall HD, Steele L, Ray PN, Nawaz Z, Baskin B, Frecker M, Carr SM, Ives E, Parfrey PS. The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland. Clin Genet. 2008 Sep;74(3):213-22. doi:10.1111/j.1399-0004.2008.01054.x. Epub 2008 Aug 4.
Schulz A, Kohlschutter A, Mink J, Simonati A, Williams R. NCL diseases - clinical perspectives. Biochim Biophys Acta. 2013 Nov;1832(11):1801-6. doi:10.1016/j.bbadis.2013.04.008. Epub 2013 Apr 17.
Sleat DE, Gin RM, Sohar I, Wisniewski K, Sklower‑Brooks S, Pullarkat RK, Palmer DN, Lerner TJ, Boustany RM, Uldall P, Siakotos AN, Donnelly RJ, Lobel P. Mutational analysis of the defective protease in classic late‑infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet. 1999 Jun;64(6):1511-23. doi:10.1086/302427.